Search clinical trials for: POL6326

Total 7 results

Polyphor Ltd.

Completed

Safety and Efficacy of POL6326 for Mobilization of Hematopoietic Stem Cells in Healthy Volunteers

Healthy

Germany
Polyphor Ltd.

Completed

Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies

Myeloproliferative Disorders | Adult Acute Lymphoblastic Leukemia in Remission | Chronic Lymphocytic Leukemia (CLL) | Myelodysplastic Syndrome (MDS) | Acute Myeloid Leukemia in Remission | Chronic Myelogenous Leukemia (CML) | Multiple Myeloma (MM) | Non-Hodgkin's Lymphoma (NHL) or Hodgkin's Disease...

United States
Polyphor Ltd.

Completed

CXCR4 Antagonism for Cell Mobilisation and Healing in Acute Myocardial Infarction (CATCH-AMI) (CATCH-AMI)

Large Reperfused ST-Elevation Myocardial Infarction

United Kingdom, Austria, Germany, Hungary, Poland
Polyphor Ltd.

Completed

Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer

Metastatic Breast Cancer

Spain, United States
Spexis AG

Terminated

Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer (FORTRESS)

Metastatic Breast Cancer | Locally Recurrent Breast Cancer

Spain, Belgium, United States, United Kingdom, Korea, Republic of, Taiwan, Italy, Russian Federation, Czechia, France, Brazil, Argentina, Ukraine
Polyphor Ltd.

Completed

Exploratory Study on POL6326 in Stem Cell Mobilization

Multiple Myeloma

Germany
MedSIR

Withdrawn

POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer (POLTER)

Advanced Breast Cancer

Search clinical trials for: POL6326

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations